Exogenous Glucose Administration Impairs Glucose Tolerance and Pancreatic Insulin Secretion during Acute Sepsis in Non-Diabetic Mice

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Watanabe, Yoshio ^a   Singamsetty, Srikanth ^a   Zou, Baobo ^a   Guo, Lanping ^a   Stefanovski, Darko ^b   Alonso, Laura C ^a   Garcia Ocana, Adolfo ^a   O'Donnell, Christopher P ^a   McVerry, Bryan J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENDOTOXEMIA; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; SEPSIS; SURVIVAL RATE;

ACUTE DISEASE; ANIMALS; CECUM; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; ENDOTOXEMIA; GLUCOSE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEMODYNAMICS; HYPERGLYCEMIA; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; LIGATION; MALE; MICE; MICE, INBRED C57BL; PANCREAS; PARENTERAL NUTRITION; PUNCTURES; SEPSIS;

MUS;

EID: 84879471023     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067716     Document Type: Article

References (27)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, et al. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310. doi:10.1097/00003246-200107000-00002. PubMed: 11445675.
2. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, et al. (2001) Intensive insulin therapy in critically ill patients. N Engl J Med 345: 1359-1367. doi:10.1056/NEJMoa011300. PubMed: 11794168.
3. Frankenfield DC, Omert LA, Badellino MM, Wiles CE 3rd, Bagley SM, et al. (1994) Correlation between measured energy expenditure and clinically obtained variables in trauma and sepsis patients. JPEN J Parenter Enteral Nutr 18: 398-403. doi:10.1177/0148607194018005398. PubMed: 7815669.
4. Finfer S, Chittock DR, Su SY, Blair D, Foster D, et al. (2009) Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360: 1283-1297. doi:10.1056/NEJMoa0810625. PubMed: 19318384.
5. Finney SJ, Zekveld C, Elia A, Evans TW, (2003) Glucose control and mortality in critically ill patients. JAMA 290: 2041-2047. doi:10.1001/jama.290.15.2041. PubMed: 14559958.
6. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, et al. (2006) Intensive insulin therapy in the medical ICU. N Engl J Med 354: 449-461. doi:10.1056/NEJMoa052521. PubMed: 16452557.
7. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, et al. (2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358: 125-139. doi:10.1056/NEJMoa070716. PubMed: 18184958.
8. Casaer MP, Mesotten D, Hermans G, Wouters PJ, Schetz M, et al. (2011) Early versus late parenteral nutrition in critically ill adults. N Engl J Med 365: 506-517. doi:10.1056/NEJMoa1102662. PubMed: 21714640.
9. Patiño JF, de Pimiento SE, Vergara A, Savino P, Rodríguez M, et al. (1999) Hypocaloric support in the critically ill. World J Surg 23: 553-559. doi:10.1007/PL00012346. PubMed: 10227923.
10. Marik PE, Raghavan M, (2004) Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 30: 748-756. doi:10.1007/s00134-004-2167-y. PubMed: 14991101.
11. Losser MR, Damoisel C, Payen D, (2010) Bench-to-bedside review: Glucose and stress conditions in the intensive care unit. Crit Care 14: 231. doi:10.1186/cc9386. PubMed: 20727232.
12. Woodske ME, Yokoe T, Zou B, Romano LC, Rosa TC, et al. (2009) Hyperinsulinemia predicts survival in a hyperglycemic mouse model of critical illness. Crit Care Med 37: 2596-2603. doi:10.1097/CCM.0b013e3181a9338a. PubMed: 19623043.
13. Agwunobi AO, Reid C, Maycock P, Little RA, Carlson GL, (2000) Insulin resistance and substrate utilization in human endotoxemia. J Clin Endocrinol Metab 85: 3770-3778. doi:10.1210/jc.85.10.3770. PubMed: 11061537.
14. Krogh-Madsen R, Møller K, Dela F, Kronborg G, Jauffred S, et al. (2004) Effect of hyperglycemia and hyperinsulinemia on the response of IL-6, TNF-alpha, and FFAs to low-dose endotoxemia in humans. Am J Physiol Endocrinol Metab 286: E766-E772. doi:10.1152/ajpendo.00468.2003. PubMed: 14722028.
15. Vila G, Maier C, Riedl M, Nowotny P, Ludvik B, et al. (2007) Bacterial endotoxin induces biphasic changes in plasma ghrelin in healthy humans. J Clin Endocrinol Metab 92: 3930-3934. doi:10.1210/jc.2007-1194. PubMed: 17666475.
16. Berk JL, Hagen JF, Beyer WH, Gerber MJ, (1970) Hypoglycemia of shock. Ann Surg 171: 400-408. doi:10.1097/00000658-197003000-00013. PubMed: 4906595.
17. Naylor JM, Kronfeld DS, (1985) In vivo studies of hypoglycemia and lactic acidosis in endotoxic shock. Am J Physiol 248: E309-E316. PubMed: 3883802.
18. Heuer JG, Sharma GR, Zhang T, Ding C, Bailey DL, et al. (2006) Effects of hyperglycemia and insulin therapy on outcome in a hyperglycemic septic model of critical illness. J Trauma 60: 865-872. doi:10.1097/01.ta.0000215565.29846.ab. PubMed: 16612310.
19. Hagiwara S, Iwasaka H, Hasegawa A, Asai N, Noguchi T, (2009) Hyperglycemia contributes to cardiac dysfunction in a lipopolysaccharide-induced systemic inflammation model. Crit Care Med 37: 2223-2227. doi:10.1097/CCM.0b013e3181a007c6. PubMed: 19487929.
20. Alonso LC, Watanabe Y, Stefanovski D, Lee EJ, Singamsetty S, et al. (2012) Simultaneous measurement of insulin sensitivity, insulin secretion and the disposition index in conscious unhandled mice. Obesity (Silver Spring) 20: 1403-1412. doi:10.1038/oby.2012.36.
21. Alonso LC, Yokoe T, Zhang P, Scott DK, Kim SK, et al. (2007) Glucose infusion in mice: a new model to induce beta-cell replication. Diabetes 56: 1792-1801. doi:10.2337/db06-1513. PubMed: 17400928.
22. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH, (2006) Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55: 390-397. doi:10.2337/diabetes.55.02.06.db05-0686. PubMed: 16443772.
23. Bergman RN, Phillips LS, Cobelli C, (1981) Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68: 1456-1467. doi:10.1172/JCI110398. PubMed: 7033284.
24. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, et al. (2002) Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110: 851-860. doi:10.1172/JCI15318. PubMed: 12235117.
25. Mehta VK, Hao W, Brooks-Worrell BM, Palmer JP, (1994) Low-dose interleukin 1 and tumor necrosis factor individually stimulate insulin release but in combination cause suppression. Eur J Endocrinol 130: 208-214. doi:10.1530/eje.0.1300208. PubMed: 8130898.
26. Sauter NS, Schulthess FT, Galasso R, Castellani LW, Maedler K, (2008) The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology 149: 2208-2218. doi:10.1210/en.2007-1059. PubMed: 18239070.
27. Wei Y, Chen K, Whaley-Connell AT, Stump CS, Ibdah JA, et al (2008) Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am J Physiol Regul Integr Comp Physiol 294: R673-680.